nach oben

Journal of Neurology

Erschienen in:

02.11.2023 | Neurological Update

Neurosarcoidosis

verfasst von: Desmond P. Kidd

Erschienen in: Journal of Neurology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Sarcoidosis affects the nervous system in 5% of cases. 60% of cases involve the cranial and peripheral nerves, the remainder the central nervous system, in which a leptomeningitis, a pachymeningitis and a vasculitis may arise. Stroke and cerebral haemorrhage may occur, and certain infections in the brain are more likely with sarcoidosis. Patients respond well to treatment but oftentimes with residual neurological impairments which may be severe. A greater understanding of the disease and the need for early treatment and use of biological therapies have improved treatment outcome in recent times.

Arkema E, Cozier YC (2018) Epdemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic dis 9:227–240PubMedPubMedCentralCrossRef

Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL (2016) Epidemiology of sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc 91:183–188PubMedCrossRef

Baughman RP, Field S, Costabel U et al (2016) Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 13:1244–1252PubMedCrossRef

Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Muller-Quernheim J (2019) Sarcoidosis. Nat Rev 5:45

Rajoriya N, Wotton CJ, Yeates DGR et al (2003) Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database. PMJ 85:233–237

Seve P, Pacheco Y, Durupt F et al (2021) Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells 10:766PubMedPubMedCentralCrossRef

Baughman RP, Teirstein AS, Judson MA et al (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889PubMedCrossRef

Judson MA, Baughman RP, Thompson BW et al (2003) ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 20:204–211PubMed

Kidd DP (2020) Neurosarcoidosis: clinical manifestations, investigation and treatment. Pract Neurol 20:199–212PubMedCrossRef

10.

Carlson M, White JR, Esahbodi M et al (2015) Cranial base manifestations of Neurosarcoidosis: a review of 305 patients. Otol Neurotol 36:156–166PubMedCrossRef

11.

Kidd DP (2018) Sarcoidosis of the central nervous system: clinical features, imaging and CSF results. J Neurol 265:1906–1915PubMedCrossRef

12.

Kidd DP, Burton BJ, Graham EM, Plant GT (2016) Optic neuropathy associated with systemic sarcoidosis. Neurol, Neuroimmunol Neuroinflamm 3:270CrossRef

13.

Webb LM, Chen JJ, Aksamit AJ et al (2021) A multi-center case series of sarcoid optic neuropathy. J Neurol Sci 420:117282PubMedCrossRef

14.

Langrand C, Bihan H, Raverot G et al (2012) Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM 105:981–995PubMedCrossRef

15.

Anthony J, Esper GJ, Ioachimescu A (2016) Hypothalamic-pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review. Pituitary 19:19–29PubMedCrossRef

16.

Kidd DP (2020) Sarcoidosis of the central nervous system: safety and efficacy of treatment, and experience of biological therapies. Clin Neurol Neurosurg 194:105811PubMedCrossRef

17.

Jachiet V, Lhote R, Rufat P et al (2018) Clinical, imaging and histological presentations and outcomes of stroke related to sarcoidosis. J Neurol 265:2333–2341PubMedCrossRef

18.

Corse AM, Stern BJ (1990) Neurosarcoidosis and stroke. Stroke 21:152–153PubMedCrossRef

19.

Gonzalez-Aramuru I, Ruiz-Perez E, Gomez-Roman J, Quince R, Larrosa D, Pascual J (2014) Sarcoidosis presenting as transient ischemic attack status. J Stroke Cerebrovasc Dis 21:515–517CrossRef

20.

Takenaka K, Ito M, Kuamagai M et al (1998) Moyamoya disease associated with pulmonary sarcoidosis: case report. Neurol Med Chir (Tokyo) 38:566–568PubMedCrossRef

21.

Ko JK, Lee SW, Choi CH (2009) Moyamoya-like vasculopathy in Neurosarcoidosis. J Korean Neurosurg Soc 45:50–52PubMedPubMedCentralCrossRef

22.

Bathla G, Abdel-Wahed L, Agarwal A et al (2021) Vascular involevement in neurosarcoidosis: early experiences from intracranial vessel wall imaging. J Neurol Neuroimmunol Neuroinflamm 8:e1063PubMedCrossRef

23.

Hutto S, Kyle K, Balaban DT, Martinez Lage M, Venna N (2022) Ischemic sroke in neurosarcoidosis: a retrospective cohort analysis. Mult Scler 68:104227

24.

O’Dwyer JP, Al-Moyeed BA, Farrell MA et al (2013) Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature. Eur J Neurol 20:71–78PubMedCrossRef

25.

Cohen-Aubart F, Galanaud D, Grabli D et al (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89:133–140PubMedCrossRef

26.

Sakushima K, Yabe I, Nakano F et al (2011) Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol 258:2163–2167PubMedCrossRef

27.

Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K (2014) Spinal cord neurosarcoidosis. Am J Med Sci 347:195–198PubMedCrossRef

28.

Durel CA, Marignier R, Maucort-Boulch D et al (2016) Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol 263:981–990PubMedCrossRef

29.

Kaiboriboon K, Olsen TJ, Hayat GR (2005) Cauda equina and conus medullaris syndrome in sarcoidosis. Neurologist 11:179–183PubMedCrossRef

30.

Miura S, Kusumoto M, Noda K et al (2007) Bell-shaped sensory impairments of all modalities in a neurosarcoidosis patient. Clin Neurol Neurosurg 109:794–798PubMedCrossRef

31.

Uzawa A, Kojima S, Yonezu T, Kanesaka T (2009) Truncal polyradiculopathy due to sarcoidosis. J Neurol Sci 281:108–109PubMedCrossRef

32.

Zuniga G, Ropper AH, Frank J (1991) Sarcoid peripheral neuropathy. Neurology 41:1558–1561PubMedCrossRef

33.

Burns TM, Dyck PJ, Aksamit AJ, Dyck PJ (2006) The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J Neurol Sci 244:77–87PubMedCrossRef

34.

Said G (2013) Sarcoidosis of the peripheral nervous system. Handb Clin Neurol 115:485–495PubMedCrossRef

35.

Tavee J (2022) Peripheral neuropathy in sarcoidosis. J Neuroimmunol 368:577864PubMedCrossRef

36.

Sawai S, Misawa S, Kobayashi M et al (2010) Multifocal conduction blocks in sarcoid peripheral neuropathy. Intern Med 49:471–474PubMedCrossRef

37.

Oh SJ (1980) Sarcoid polyneuropathy: a histologically proved case. Ann Neurol 7:178–181PubMedCrossRef

38.

Said G, Lacroix C, Planté-Bordeneuve V et al (2002) Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain 125:264–675PubMedCrossRef

39.

Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C (2008) Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropathol 27:96–105PubMedCrossRef

40.

Hoitsma E, Marziniak M, Faber CC et al (2002) Small fibre neuropathy in sarcoidosis. Lancet 359:2085–2086PubMedCrossRef

41.

Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA (2017) Sarcoidosis-associated small fibre neuropathy in a large cohort: clinical aspects and response to IVIg and anti-TNF alpha treatment. Respir Med 26:135–213CrossRef

42.

Garret M, Pestronk A (2022) Sarcoidosis, granulomas and myopathy syndromes: a clinic-pathological review. J Neuroimmunol 373:577975PubMedCrossRef

43.

Cohen Aubart F, Abbara S, Maisonobe T et al (2018) Symptomatic muscular sarcoidosis: lessons from a nationawide multicentre study. Neurol Neuroimmunol Neuroinflamm 16:e452CrossRef

44.

Ten Dam L, Raaphorst J, van der Kooi AJ et al (2022) Clinical characteristics and outcome in muscular sarcoidosis: a retrospective cohort study and literature review. Neuromuscul Disord 32:557–563PubMedCrossRef

45.

Wengert O, Rothenfusser-Korber E, Vollrath B et al (2013) Neurosarcoidosis: correlation of cerebrospinal fluid findings wit diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 335:124–130PubMedCrossRef

46.

Chazal T, Christopoulos M, Maillert E et al (2019) The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in Neurosarcoidosis: a multicentre, pragmatic, comparative study. Eur J Neurol 26:1274–1280PubMedCrossRef

47.

Paley MA, Baker BJ, Dunham SR et al (2022) The CSF in neurosarcoidosis contains consistent cloncal expansion of CD8 T cells, but not CD4 T cells. J Neuroimmunol 367:577860PubMedPubMedCentralCrossRef

48.

Otto C, Wengert O, Unterwalder N, Meisel C, Ruprecht K (2020) Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm 11:e725CrossRef

49.

Byg KE, Illes Z, Sejbaek T, Lambertsen KL, Ellingsen T, Nielsen HH (2022) Inflammatory profiles in plasma and cerebrospinal fluid of patients with neurosarcoidosis. J Neuroimmunol 367:577849PubMedCrossRef

50.

Riviere E, Schwartz P, Machelart I et al (2019) Neurosarcoidosis and infliximab therapy monitored by 18-FDG PET/CT. QJM 112:695–697PubMedCrossRef

51.

Bartels S, Kyavar L, Blumstein N et al (2013) FDG PET findings leading to the diagnosis of neurosarcoidosis. Clin Neurol Neurosurgery 115:85–88CrossRef

52.

Seniaray N, Jain A (2019) 18-F fluorodeoxyglucose positron emission tomography – computed tomography / magnetic resonance imaging in neurosarcoidosis. Indian J Nucl Med 34:344–346PubMedPubMedCentralCrossRef

53.

Regis C, Benali K, Rouzet F (2023) FDG PET/CT imaging of sarcoidosis. Semin Nucl Med 53:258–272PubMedCrossRef

54.

Fritz D, van den Beek D, Brouwer MC, Booij J (2020) Whole body 18F-FDG PET-CT in the diagnosis of neurosarcoidosis. Mayo Clin Proc 95:1082–1084PubMedCrossRef

55.

Huang JF, Aksemit AJ, Staff N (2012) MRI and PET imaging discordance in Neurosarcoidosis. Neurology 79:1070PubMedCrossRef

56.

Judson MA, Costabel U, Drent M et al (2014) The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarc Vasc Diffuse Lung Dis 31:19–27

57.

Stern BJ, Royal W, Gelfand JM et al (2018) Definition and consensus diagnostic criteria for Neurosarcoidosis from the Neurosarcoidosis consortium consensus group. JAMA Neurol 75:1546–1553PubMedCrossRef

58.

Baughman RP, Lower EE (2015) Treatment of Sarcoidosis. Clin Rev Allergy Immunol 49:79–92PubMedCrossRef

59.

Bitoun S, Bouvry D, Borie R et al (2016) Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology 87:1–5CrossRef

60.

Joubert B, Chapelon-Abric C, Biard L et al (2017) Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol 74:1336–1344PubMedPubMedCentralCrossRef

61.

Saketkoo LA, Baughman RP (2016) Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol 12:817–825PubMedCrossRef

62.

Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C et al (2018) Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicentre study of 132 patients. Semin Arth Rheum 47:288–294CrossRef

63.

Cohen-Aubart F, Bouvry D, Galanaud D et al (2017) Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol 264:891–897PubMedCrossRef

64.

Gelfand JM, Bradshaw MJ, Stern BJ et al (2017) Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 89:2092–2100PubMedPubMedCentralCrossRef

65.

Kidd DP, Galloway M, Wilhelm T (2020) Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar. Neurology 94:991–993PubMedCrossRef

66.

Riller Q, Cotteret C, Junot H et al (2019) Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. J Neurol 266:1073–1078PubMedCrossRef

67.

Sharp M, Donnelly SC, Moller DR (2019) Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med J 1:100004

68.

Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla, Thone J (2018) Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord 11:1756286418805732PubMedPubMedCentralCrossRef

69.

Judson MA, Baughman RP, Costabel U et al (2014) Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 44:1296–1307PubMedCrossRef

70.

Zhou T, Casanova N, Pouladi N et al (2017) Identification of Jak-STAT signalling involvement in sarcoidosis severity via a novel micro-RNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep 26:4237CrossRef

71.

Damsky W, Thakral D, Emeagwali N, Galan A, King B (2018) Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med 379:2540–2546PubMedPubMedCentralCrossRef

72.

Hoitsma E, Faber CG, van Santen-Hoeufft M, de Vries J, Reulen JP, Drent M (2006) Improvement of small fibre neuropathy in a sarcoidosis patient after treatment with infliximab. Sarc Vasc Diff Lung Dis 23:73–77

Titel: Neurosarcoidosis
verfasst von: Desmond P. Kidd
Publikationsdatum: 02.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 2/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12046-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

The DeMyers: Marian (1922–2012) and William (1924–2008)

The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis

Brain 18F-FDG PET findings and sequential vestibular testing in SCA27B: a case report

Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis

AMPK role in epilepsy: a promising therapeutic target?